Valion Bio Appoints Melinda Lackey as General Counsel
Rhea-AI Summary
Valion Bio (Nasdaq: VBIO) appointed Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, effective May 4, 2026. Ms. Lackey brings nearly two decades of combined scientific, IP, clinical-stage, and Nasdaq public company experience.
Her background includes senior legal roles at Alaunos Therapeutics and Kuur Therapeutics, patent litigation experience at Winston & Strawn and Howrey, and early research roles at UT Health Science Center and MD Anderson. The hire is positioned to support Entolimod's FDA Animal Rule pathway, an ongoing capital raise, and scaling of the Velocity Bioworks CDMO in San Antonio.
AI-generated analysis. Not financial advice.
Positive
- Appoints GC with nearly two decades of biotech IP and public-company experience
- In-house legal support for Entolimod’s FDA Animal Rule pathway
- Legal leadership to support scaling of Velocity Bioworks CDMO
Negative
- None.
News Market Reaction – TCRT
On the day this news was published, TCRT gained 3.16%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
TCRT is up 2.35% with mixed peer moves: APVO, ADTX and XBIO are also positive, while GRI and CMND are negative, suggesting company-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Preclinical data update | Positive | +4.1% | Positive non‑GLP preclinical obesity data for ALN1003 in DIO mouse models. |
Limited history, but prior positive R&D data was followed by an aligned positive price reaction.
Recent news flow for Alaunos (TCRT) has focused on its obesity candidate ALN1003. On Mar 2, 2026, the company reported positive non‑GLP preclinical mouse data, with improvements in weight, liver metrics, and metabolic markers. Shares rose about 4.08% over the next 24 hours, indicating that the market responded favorably to credible scientific progress. Today’s news relates to a former executive joining Valion Bio rather than a direct development in TCRT’s own pipeline.
Regulatory & Risk Context
TCRT has an active S-3/A mixed shelf filed on 2025-11-07, registering up to $50,000,000 of primary securities plus specified resale shares. The shelf was pre‑effective in the filing summary, with 0 recorded usage in the provided data.
Market Pulse Summary
This announcement highlights that Alaunos’ former Senior Vice President of Legal & Administration has joined Valion Bio as General Counsel, underscoring her background in immunotherapy, IP strategy, and Nasdaq governance. For TCRT, it signals an executive transition rather than a direct pipeline or financial update. In context of prior positive ALN1003 preclinical data and an unused $50,000,000 shelf, investors might focus on future disclosures about leadership, funding plans, and progress of the obesity program.
Key Terms
immunotherapeutics medical
cell therapy medical
intellectual property financial
cdmo technical
fda animal rule regulatory
innate immunity medical
AI-generated analysis. Not financial advice.
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team
Ms. Lackey joins from Alaunos Therapeutics (Nasdaq: TCRT), a clinical trial-stage oncology cell therapy company, where she served as Senior Vice President of Legal & Administration. In that role, she managed all legal and compliance functions for the publicly traded immunology company, navigating complex clinical development, regulatory strategy, and capital markets obligations. Prior to Alaunos, she served as Senior Legal Counsel at Kuur Therapeutics, a clinical trial-stage biopharmaceutical company focused on cellular immunotherapies, where she developed expertise in the legal architecture of next-generation immunological platforms.
Before transitioning in-house, Ms. Lackey was an associate at Winston & Strawn LLP and Howrey LLP, two firms with nationally recognized intellectual property and life sciences practices, where she built a strong foundation in patent litigation and prosecution, IP portfolio strategy, and biopharmaceutical transactions. Her legal training is further distinguished by an early career as a Research Associate at the University of Texas Health Science Center at
The appointment comes as Valion Bio is in the process of advancing Entolimod™ toward an FDA Animal Rule approval pathway for ARS, and scaling its wholly owned CDMO subsidiary Velocity Bioworks in
"Melinda's appointment reflects Valion Bio's direction. She has built her career at the intersection of cutting-edge immunotherapy and the legal strategy that protects it, from the bench at MD Anderson to senior legal leadership at a Nasdaq-listed cell therapy company. As we work to execute our capital raise, advance Entolimod™ through the Animal Rule pathway, and scale Velocity Bioworks, having an in-house General Counsel with her depth of scientific literacy, IP acumen, and public company experience is a strategic imperative," said Michael K. Handley, Chief Executive Officer of Valion Bio, Inc.
Ms. Lackey commented, "I am excited to join Valion Bio at such a consequential moment in its evolution. The science behind Entolimod™ and Entolasta™ is compelling, and the combination of a clinical-stage pipeline, a government-aligned countermeasures program, and a fully operational CDMO subsidiary creates a legal environment that demands both precision and creativity. I look forward to contributing to the company's mission of activating innate immunity to protect and extend life."
About Valion Bio, Inc.
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome (ARS) via the FDA Animal Rule pathway, oncology supportive care (neutropenia), and longevity indications. Entolimod™ has received Fast Track and Orphan Drug designations from the
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other
Investor Contact
vbio@cg.capital
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-appoints-melinda-lackey-as-general-counsel-302761784.html
SOURCE Valion Bio, Inc.